...
search icon
nktr-img

Nektar Therapeutics Share Price

NKTR
NAQ
$71
+$4.65
(7.01%)
1D
Industry: Pharmaceuticals Sector: Health Care

Nektar Therapeutics Analyst Forecast

Nektar Therapeutics Share Price Chart

Nektar Therapeutics Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.35B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
4.78M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.33
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.45 L
$67.94 H
$71

About Nektar Therapeutics, Common Stock

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California. more

Industry: PharmaceuticalsSector: Health Care

Nektar Therapeutics Stock Returns

Time FrameNKTRSectorS&P500
1-Week Return102.16%0.91%2.13%
1-Month Return83.13%-0.72%-0.47%
3-Month Return23.11%2.24%1.29%
6-Month Return200.85%19.1%7.71%
1-Year Return548.4%7.15%14.7%
3-Year Return53.68%16.96%67.75%
5-Year Return-79.29%33.23%76.25%
10-Year Return-58.98%142.74%271.83%

Nektar Therapeutics Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue152.91M101.91M92.06M90.12M98.43M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":66.64,"profit":true},{"date":"2022-12-31","value":60.2,"profit":true},{"date":"2023-12-31","value":58.94,"profit":true},{"date":"2024-12-31","value":64.37,"profit":true}]
Cost of Revenue19.48M24.90M21.64M36.64M30.69M[{"date":"2020-12-31","value":53.15,"profit":true},{"date":"2021-12-31","value":67.94,"profit":true},{"date":"2022-12-31","value":59.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":83.74,"profit":true}]
Gross Profit133.44M77.01M70.42M53.48M67.74M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":57.71,"profit":true},{"date":"2022-12-31","value":52.77,"profit":true},{"date":"2023-12-31","value":40.08,"profit":true},{"date":"2024-12-31","value":50.77,"profit":true}]
Gross Margin87.26%75.57%76.50%59.34%68.82%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":86.6,"profit":true},{"date":"2022-12-31","value":87.66,"profit":true},{"date":"2023-12-31","value":68,"profit":true},{"date":"2024-12-31","value":78.87,"profit":true}]
Operating Expenses513.36M523.11M310.66M190.90M172.94M[{"date":"2020-12-31","value":98.14,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.39,"profit":true},{"date":"2023-12-31","value":36.49,"profit":true},{"date":"2024-12-31","value":33.06,"profit":true}]
Operating Income(379.92M)(446.10M)(240.24M)(137.43M)(105.20M)[{"date":"2020-12-31","value":-37992200000,"profit":false},{"date":"2021-12-31","value":-44610300000,"profit":false},{"date":"2022-12-31","value":-24023600000,"profit":false},{"date":"2023-12-31","value":-13742500000,"profit":false},{"date":"2024-12-31","value":-10519800000,"profit":false}]
Total Non-Operating Income/Expense(82.86M)(121.92M)(146.99M)(146.88M)(27.61M)[{"date":"2020-12-31","value":-8286100000,"profit":false},{"date":"2021-12-31","value":-12192100000,"profit":false},{"date":"2022-12-31","value":-14699100000,"profit":false},{"date":"2023-12-31","value":-14688100000,"profit":false},{"date":"2024-12-31","value":-2761400000,"profit":false}]
Pre-Tax Income(443.95M)(523.28M)(364.98M)(276.26M)(119.20M)[{"date":"2020-12-31","value":-44394700000,"profit":false},{"date":"2021-12-31","value":-52328000000,"profit":false},{"date":"2022-12-31","value":-36498300000,"profit":false},{"date":"2023-12-31","value":-27625600000,"profit":false},{"date":"2024-12-31","value":-11920000000,"profit":false}]
Income Taxes493.00K557.00K3.21M(200.00K)(239.00K)[{"date":"2020-12-31","value":15.33,"profit":true},{"date":"2021-12-31","value":17.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-6.22,"profit":false},{"date":"2024-12-31","value":-7.43,"profit":false}]
Income After Taxes(444.44M)(523.84M)(368.20M)(276.06M)(118.96M)[{"date":"2020-12-31","value":-44444000000,"profit":false},{"date":"2021-12-31","value":-52383700000,"profit":false},{"date":"2022-12-31","value":-36819800000,"profit":false},{"date":"2023-12-31","value":-27605600000,"profit":false},{"date":"2024-12-31","value":-11896100000,"profit":false}]
Income From Continuous Operations(444.44M)(523.84M)(368.20M)(293.67M)(118.96M)[{"date":"2020-12-31","value":-44444000000,"profit":false},{"date":"2021-12-31","value":-52383700000,"profit":false},{"date":"2022-12-31","value":-36819800000,"profit":false},{"date":"2023-12-31","value":-29366500000,"profit":false},{"date":"2024-12-31","value":-11896100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(444.44M)(523.84M)(368.20M)(276.06M)(118.96M)[{"date":"2020-12-31","value":-44444000000,"profit":false},{"date":"2021-12-31","value":-52383700000,"profit":false},{"date":"2022-12-31","value":-36819800000,"profit":false},{"date":"2023-12-31","value":-27605600000,"profit":false},{"date":"2024-12-31","value":-11896100000,"profit":false}]
EPS (Diluted)(2.24)(2.85)(1.97)(1.05)(0.77)[{"date":"2020-12-31","value":-224,"profit":false},{"date":"2021-12-31","value":-285,"profit":false},{"date":"2022-12-31","value":-197,"profit":false},{"date":"2023-12-31","value":-105,"profit":false},{"date":"2024-12-31","value":-77,"profit":false}]

Nektar Therapeutics Ratios

Nektar Therapeutics Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

NKTR
Cash Ratio 4.07
Current Ratio 4.24

Nektar Therapeutics Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NKTR
ROA (LTM) -27.98%
ROE (LTM) -180.24%

Nektar Therapeutics Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NKTR
Debt Ratio Lower is generally better. Negative is bad. 0.72
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.28

Nektar Therapeutics Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NKTR
Trailing PE NM
Forward PE NM
P/S (TTM) 21.55
P/B 13.39
Price/FCF NM
EV/R 15.35
EV/Ebitda NM
PEG 3.22

FAQs

What is Nektar Therapeutics share price today?

Nektar Therapeutics (NKTR) share price today is $71

Can Indians buy Nektar Therapeutics shares?

Yes, Indians can buy shares of Nektar Therapeutics (NKTR) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NKTR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Nektar Therapeutics be purchased?

Yes, you can purchase fractional shares of Nektar Therapeutics (NKTR) via the Vested app. You can start investing in Nektar Therapeutics (NKTR) with a minimum investment of $1.

How to invest in Nektar Therapeutics shares from India?

You can invest in shares of Nektar Therapeutics (NKTR) via Vested in three simple steps:

  • Click on Sign Up or Invest in NKTR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Nektar Therapeutics shares
What is Nektar Therapeutics 52-week high and low stock price?

The 52-week high price of Nektar Therapeutics (NKTR) is $67.94. The 52-week low price of Nektar Therapeutics (NKTR) is $6.45.

What is Nektar Therapeutics price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Nektar Therapeutics (NKTR) is

What is Nektar Therapeutics price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Nektar Therapeutics (NKTR) is 13.39

What is Nektar Therapeutics dividend yield?

The dividend yield of Nektar Therapeutics (NKTR) is 0.00%

What is the Market Cap of Nektar Therapeutics?

The market capitalization of Nektar Therapeutics (NKTR) is $1.35B

What is Nektar Therapeutics's stock symbol?

The stock symbol (or ticker) of Nektar Therapeutics is NKTR

How Can Investors Use Nektar Therapeutics Share Price Data for Long-Term Investment Decisions?

Consider the share price of Nektar Therapeutics as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Nektar Therapeutics has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Nektar Therapeutics shares for Indian investors?

When investing in Nektar Therapeutics shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Nektar Therapeutics stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Nektar Therapeutics share price with other stocks in the same sector?

Rather than merely checking the share price of Nektar Therapeutics and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Nektar Therapeutics stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top